S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)

Collegium Pharmaceutical - COLL Stock Forecast, Price & News

$16.02
+0.18 (+1.14%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$15.93
$16.64
50-Day Range
$15.46
$20.10
52-Week Range
$14.04
$22.89
Volume
247,446 shs
Average Volume
324,271 shs
Market Capitalization
$546.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.25

Collegium Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
107.6% Upside
$33.25 Price Target
Short Interest
Bearish
11.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.78
Upright™ Environmental Score
News Sentiment
1.88mentions of Collegium Pharmaceutical in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$703,306 Sold Last Quarter
Proj. Earnings Growth
29.69%
From $4.21 to $5.46 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

336th out of 1,093 stocks

Pharmaceutical Preparations Industry

150th out of 547 stocks

COLL stock logo

About Collegium Pharmaceutical (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Receive COLL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

COLL Stock News Headlines

Collegium Pharmaceutical Q2 2022 Earnings Preview
Collegium Pharmaceutical Inc Stock Quote COLL
7 Micro-Cap Stocks to Take a Chance on Now
Analyst Ratings For Collegium Pharmaceutical
See More Headlines
Receive COLL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

COLL Company Calendar

Last Earnings
8/04/2022
Today
9/30/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:COLL
Fax
N/A
Employees
152
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$33.25
High Stock Price Forecast
$42.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+107.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$71.52 million
Pretax Margin
-16.69%

Debt

Sales & Book Value

Annual Sales
$276.87 million
Cash Flow
$2.23 per share
Book Value
$5.87 per share

Miscellaneous

Free Float
32,645,000
Market Cap
$546.70 million
Optionable
Optionable
Beta
0.86

Key Executives

  • Mr. Michael Thomas Heffernan B.S. PharmMr. Michael Thomas Heffernan B.S. Pharm (Age 58)
    R.Ph., Co-Founder & Chairman
    Comp: $110k
  • Mr. Joseph J. CiaffoniMr. Joseph J. Ciaffoni (Age 51)
    Pres, CEO & Director
    Comp: $1.1M
  • Ms. Colleen  TupperMs. Colleen Tupper (Age 46)
    Exec. VP & CFO
    Comp: $631.24k
  • Ms. Shirley R. KuhlmannMs. Shirley R. Kuhlmann (Age 38)
    Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec.
    Comp: $620.1k
  • Mr. Scott  DreyerMr. Scott Dreyer (Age 49)
    Exec. VP & Chief Commercial Officer
    Comp: $591k
  • Dr. Richard Malamut M.D. (Age 62)
    Exec. VP & Chief Medical Officer
    Comp: $612.2k
  • Ms. Alex Dasalla
    Head of Investor Relations
  • Mr. Bart J. Dunn
    Exec. VP of Strategy & Corp. Devel.
  • Ms. Marlo Manning
    Head of HR
  • Mr. Scott Sudduth
    Head of Technical Operations













COLL Stock - Frequently Asked Questions

Should I buy or sell Collegium Pharmaceutical stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" COLL shares.
View COLL analyst ratings
or view top-rated stocks.

What is Collegium Pharmaceutical's stock price forecast for 2022?

4 Wall Street research analysts have issued 12 month price targets for Collegium Pharmaceutical's shares. Their COLL share price forecasts range from $26.00 to $42.00. On average, they expect the company's stock price to reach $33.25 in the next year. This suggests a possible upside of 106.3% from the stock's current price.
View analysts price targets for COLL
or view top-rated stocks among Wall Street analysts.

How have COLL shares performed in 2022?

Collegium Pharmaceutical's stock was trading at $18.68 on January 1st, 2022. Since then, COLL shares have decreased by 13.7% and is now trading at $16.12.
View the best growth stocks for 2022 here
.

When is Collegium Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our COLL earnings forecast
.

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) issued its quarterly earnings results on Thursday, August, 4th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $1.15 by $1.19. The specialty pharmaceutical company earned $123.55 million during the quarter, compared to the consensus estimate of $122.63 million. Collegium Pharmaceutical had a negative net margin of 11.24% and a negative trailing twelve-month return on equity of 2.12%.

What guidance has Collegium Pharmaceutical issued on next quarter's earnings?

Collegium Pharmaceutical updated its FY 2022 earnings guidance on Thursday, August, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $450.00 million-$465.00 million, compared to the consensus revenue estimate of $455.26 million.

What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO?

6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $16.12.

How much money does Collegium Pharmaceutical make?

Collegium Pharmaceutical (NASDAQ:COLL) has a market capitalization of $550.18 million and generates $276.87 million in revenue each year. The specialty pharmaceutical company earns $71.52 million in net income (profit) each year or ($1.05) on an earnings per share basis.

How many employees does Collegium Pharmaceutical have?

The company employs 152 workers across the globe.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The official website for the company is www.collegiumpharma.com. The specialty pharmaceutical company can be reached via phone at (781) 713-3699 or via email at info@collegiumpharma.com.

This page (NASDAQ:COLL) was last updated on 9/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.